Idiopathic Pulmonary Fibrosis Advances in Diagnostic Tools and Disease Management /
From epidemiology and pathogenesis to disease management, this book reviews our current understanding of and provides up-to-date information of Idiopathic Pulmonary Fibrosis (IPF). A subtype of Idiopathic Interstitial Pneumonias (IIP), IPF is one of the most elusive and intractable respiratory disea...
| Corporate Author: | |
|---|---|
| Other Authors: | , |
| Language: | English |
| Published: |
Tokyo :
Springer Japan : Imprint: Springer,
2016.
|
| Edition: | 1st ed. 2016. |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/978-4-431-55582-7 |
Table of Contents:
- Part 1
- Definition, epidemiology, and pathogenesis
- Chapter 1: Definition of IPF (Question: Is the latest classification [ATS/ERS] satisfactory?)
- Chapter 2: Epidemiology and risk factors of IPF (Question: Can we dare to ask, “What are the possible causes?”)
- Chapter 3: Acute exacerbation of IPF (Question: The concept was proposed in Japan, but why was it not recognized in western countries?)
- Chapter 4: Pathogenesis (Question: Is abnormal repair of epithelial damage involved in the basic pathogenesis of this disease?)
- Part 2 Diagnosis
- Chapter 5: Specific serum markers of IPF (Question: What are the significances of KL-6, SP-A, and SP-D?)
- Chapter 6: High-resolution CT of honeycombing and IPF/UIP (Question: To what extent can honeycomb lung be diagnosed by imaging? To what extent can IPF diagnosis be made by HRCT?)
- Chapter 7: Pathology of IPF (Question: Why does the pathological classification of IIPs vary among pathologists?)
- Chapter 8: Differential diagnosis (Question: What should we particularly keep in mind in the differential diagnosis?)
- Part 3 Management and prognosis
- Chapter 9 Pharmacotherapy of IPF (antifibrotic compounds) (Question: Can antifibrotic agents really inhibit fibrosis? How about the development of new therapeutic agents?)
- Chapter 10: Pharmacotherapy of IPF (Corticosteroids, immunosuppressants) (Question: Are these actually effective? Ineffective? Harmful?)
- Chapter 11: Non-pharmacological therapy for IPF (Question: Is respiratory care actually effective?)
- Chapter 12: Pharmacotherapy of acute exacerbation of IPF (Corticosteroids, immunosuppressants and direct hemoperfusion with polymyxin B) (Question: Are high-dose steroid therapy, other immunosuppressant therapy, and PMX therapy [often used in Japan] really effective?)
- Part 4 Topics
- Chapter 13 :Combined pulmonary fibrosis and emphysema (CPFE) (Question: Is it an independent disease entity?)
- Chapter 14: Common pathways in IPF and lung cancer (Question: Why is lung cancer associated with IPF at a high frequency?)
- Chapter 15 :Acute exacerbation of IIPs after pulmonary resection for lung cancer (Question: Can acute exacerbation of IPF be predicted preoperatively?) .